Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial.

PROs by clinical outcomes When mean change from baseline to week 26 in TRIM‐D total scores was assessed according to change in HbA1c, change in body weight, hypoglycaemia incidence and reaching the composite target (HbA1c < 7% with no weight gain and no hypoglycaemia [<3.9 mmol/L, <70 mg/dl]) (Figure 4 ), there was an overall trend of a greater difference from baseline in TRIM‐D scores in participants receiving iGlarLixi compared with those receiving BIAsp 30 across all subgroups.

also in 4,871 other papers